To include your compound in the COVID-19 Resource Center, submit it here.

Amgen's denosumab misses in Phase III as adjuvant treatment for breast cancer

Amgen Inc. (NASDAQ:AMGN) and partner Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported top-line data from the Phase III D-CARE trial in

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE